MétaCan
Menu
← Back to cohort
Record W4411929989 · doi:10.1016/j.vaccine.2025.127423

COVID-19 vaccine uptake and effectiveness among people with recent history of injection drug use in British Columbia, Canada: A retrospective analysis

2025· article· en· W4411929989 on OpenAlexafffundabout
James Wilton, Héctor Alexander Velásquez García, Zaeema Naveed, Alexis Crabtree, Jane A. Buxton, Jason Wong, Mel Krajden, Hind Sbihi, Naveed Z. Janjua

Bibliographic record

VenueVaccine · 2025
Typearticle
Languageen
FieldMedicine
TopicHIV, Drug Use, Sexual Risk
Canadian institutionsSt. Paul's HospitalVancouver Hospital and Health Sciences CentreBC Centre for Disease Control
FundersCanadian Institutes of Health ResearchCanadian Immunization Research NetworkPublic Health Agency of Canada
KeywordsCoronavirus disease 2019 (COVID-19)VirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Medicine2019-20 coronavirus outbreakDrugInjection drug useRetrospective cohort studyFamily medicinePharmacologyOutbreakDrug injectionSurgeryInfectious disease (medical specialty)Internal medicineDisease

Abstract

fetched live from OpenAlex

BACKGROUND: It is a public health priority to assess vaccine impact in marginalized populations disproportionately affected by COVID-19 to inform population-specific policies and reduce health disparities. We assessed COVID-19 vaccine uptake and effectiveness among people who inject drugs (PWID) in British Columbia, Canada. METHODS: We used a population-based, linked data platform and a validated algorithm with high specificity to create a cohort of people aged 18-65 years with recent history of injection drug use (PWID). Vaccine uptake was assessed from Dec 15, 2020 (vaccine rollout) to the end of 2022. mRNA vaccine effectiveness against infection and severe outcomes was estimated using the test-negative study design during a period of Delta emergence/predominance (May 30th, 2021 to Nov 27th, 2021). We matched non-PWID to PWID on sociodemographics to create a comparison group. RESULTS: The cohort included 26,581 PWID, of whom a subset (1188 test-positive cases, 169 severe outcomes) were included in vaccine effectiveness analyses. By the end of 2022, the percentage of PWID vs. non-PWID who had received a vaccine dose was 72.6 % vs. 83.0 % (1st dose) and 64.7 % vs. 81.1 % (2nd dose). Vaccine effectiveness within 7-179 days after 2nd dose among PWID was 80.0 % (95 % CI 76.1-83.3 %) against infection and 92.9 % (95 % CI 88.2-95.7 %) against severe outcomes. Equivalent estimates for non-PWID were 90.0 % (95 %CI 89.3-90.7 %) and 98.7 % (95 %CI 98.1-99.2 %). CONCLUSIONS: Vaccine uptake and effectiveness were substantial among people with recent history of injection drug use, but somewhat lower relative to non-PWID matched on sociodemographic characteristics. While results suggest vaccines likely played a large role in reducing the population-level impact of COVID-19 among PWID, our results also highlight a potentially avoidable excess disease burden. Results should be interpreted within the context of the pervasive marginalization of people who use drugs. Findings may also have implications for vaccine outreach efforts and booster dose prioritisation.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.004
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.022
Threshold uncertainty score0.162

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.004
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0030.007
Science and technology studies0.0020.001
Scholarly communication0.0010.000
Open science0.0020.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.012
GPT teacher head0.257
Teacher spread0.246 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes3
Has abstractyes

Explore more

Same venueVaccine→Same topicHIV, Drug Use, Sexual Risk→French-language works237,207→